Global Orphan Drugs Market: Industry Analysis & Outlook (2018-2022)

Wednesday, July 25, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, July 25, 2018 /PRNewswire/ -- Orphan diseases are typically life-threatening or chronically debilitating for which

no or inadequate alternative treatments are available.Download the full report: https://www.reportbuyer.com/product/4968942 An orphan disease refers to any rare disease which affects a smaller share of population. Most of the rare diseases
are genetic and therefore chronic. Presently, there are around 7000 rare diseases affecting approximately 5-6% of the global population. Half of the population of orphan disease patients is children as most of the genetic orphan diseases occur at birth or childhood.Generally, orphan diseases are considered to be severe, progressive, degenerative, life-threatening or chronically debilitating diseases which can be caused genetically, infectiously or toxically. Despite knowing the causes of orphan diseases, most of these diseases are still non-curable or lack satisfactory treatments. Majority of the genetic orphan diseases are caused by defects in a single gene due to multiple mutations.Orphan drug market is likely to witness a growth in future with increasing development and approvals of ultra-rare drugs and rising developments in drugs for rare blood disease. The US and Europe are the major contributors to the global orphan drugs market supported by increased numbers of orphan drug designations. Asia is likely to experience further growth with increasing orphan designations in Japan and improving healthcare facilities.The global orphan drugs market is expected to grow in future due to prolonged orphan drug market exclusivity, increasing sales of prescription drugs, attractive orphan drug policies, rising healthcare expenditure, improving economies and increasing prevalence of chronic diseases. Key trends & development of this market include rise in orphan drug approvals, accelerating pipeline sales of orphan drugs, development of drug therapies and rising scope in gene therapy. However, there are some factors which can hinder growth of the market including high costs of drugs, increased competition from generic industry, insufficient disease information & research participants and deficiency of diagnostic systems and trained professionals.The report "Global Orphan Drugs Market: Industry Analysis & Outlook (2018-2022)" by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the US, Europe and Asia along with the global market. The report profiles key players of the market including Roche holding AF, Novartis International AG, Bristol-Myers Squibb and Celgene Corporation.Download the full report: https://www.reportbuyer.com/product/4968942 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: sarah@reportbuyer.com Tel: +1 (718) 213 4904 Website: www.reportbuyer.com

Cision View original content:http://www.prnewswire.com/news-releases/global-orphan-drugs-market-industry-analysis--outlook-2018-2022-300686444.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store